Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective ...

0001); using on treatment data, the reductions were 16.6% vs 2.7%, respectively. Weight loss of 5% or greater was achieved by 79.2% of patients on semaglutide 25mg vs 31.1% of those on placebo (P ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...